Company intelligence / Profile preview
Homburg
- Ownership
- Private
- Development stage
- Other
Overview
Homburg Pharma, historically known as Chemiewerk Homburg AG, was a prominent German pharmaceutical company that operated as a subsidiary of Degussa. The company was a pioneer in the development of alkylating agents for oncology, most notably contributing to the discovery and commercialization of ifosfamide and cyclophosphamide. Beyond oncology, Homburg was instrumental in the development of psychotropic medications, including the tricyclic antidepressant doxepin. In 1978, the company was merged with ASTA-Werke to form ASTA Medica, which was later dismantled and sold to various international pharmaceutical entities. Today, the legacy of Homburg lives on through the continued clinical use of its foundational small molecule therapies in cancer and mental health.
- Therapeutic areas
- OncologyPsychiatry
- Modalities
- Small molecule
- Industry
- Pharma
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Homburg.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Homburg.